Novo-nordisk As Stock
€59.29
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Novo-nordisk As
sharewise wants to provide you with the best news and tools for Novo-nordisk As, so we directly link to the best financial data sources.
Financials
News
Novo Nordisk Stock: AI Partnership Boosts Obesity Drug Pipeline
The Danish pharmaceutical giant Novo Nordisk is making strategic moves that have investors taking notice. On June 12, 2025, the company announced its obesity drug candidate Amycretin would advance
Novo Nordisk Stock: CEO Exit Signals Leadership Crisis
The Danish pharmaceutical giant Novo Nordisk announced Friday that CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, sending shockwaves through the investment community
Novo Nordisk Stock: Billions Bet on Obesity Pill Future
Novo Nordisk is making waves in the biotech sector with a strategic partnership worth up to $2.2 billion with US-based Septerna. The Danish pharmaceutical giant will provide more than $200 million
Novo Nordisk Stock: Trump Policy Triggers Market Turbulence
The Danish pharmaceutical giant Novo Nordisk experienced significant stock volatility following former US President Donald Trump's announcement of a potential drug pricing decree. The company's
Novo Nordisk Stock: Trump Plan Threatens, Research Brightens Outlook
Novo Nordisk shares experienced significant volatility recently as political developments from the United States sparked concerns among investors. US President Donald Trump announced plans to
Novo Nordisk Stock: Gains Despite 2025 Forecast Cut
Danish pharmaceutical giant Novo Nordisk saw its stock rise 1.3% to 446.80 Danish kroner on Wednesday, despite lowering its 2025 growth targets. The company reduced its revenue growth forecast from
Novo Nordisk Stock: Sharp Decline Offers Potential Entry Point
After a remarkable ascent that crowned Novo Nordisk as Europe's most valuable publicly traded company, the Danish pharmaceutical giant has encountered turbulent waters. The stock, which once
Novo Nordisk Stock: Supply Breakthrough Strengthens Market Position
Danish pharmaceutical giant Novo Nordisk has achieved a significant milestone in addressing the supply constraints of its popular weight-loss medications, Ozempic and Wegovy. Following a two-year